MedTrace Logo

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

NCT07454941 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2026-03-06

No results posted yet for this study

Summary

This study aims to build upon previous research by using artificial intelligence methods to fuse multimodal data from imaging and pathology to construct a predictive model for HER2 expression in urothelial carcinoma. The model's performance will be validated and optimized using a multicenter cohort study, ultimately achieving accurate and rapid prediction of HER2 expression. This will guide precise decision-making for further HER2-targeted therapy and improve patient prognosis. Big data analysis and deep learning will also assist physicians in more accurately diagnosing the disease and developing personalized treatment plans. The research findings will promote the integration and development of artificial intelligence technology with the healthcare industry in the application of multimodal data from clinical, imaging, and pathology perspectives.

Conditions

  • Urothelial Carcinoma (UC)
  • HER2
  • Diagnostic

Sponsors & Collaborators

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Huadong Hospital

    collaborator OTHER

  • Huaxi Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2028-06-03
Completion
2030-06-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07454941 on ClinicalTrials.gov